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A Four-Biomarker Blood 
Signature Discriminates Systemic 
Inflammation Due to Viral Infection 
Versus Other Etiologies
D. L. Sampson1, B. A. Fox1, T. D. Yager1, S. Bhide1, S. Cermelli1, L. C. McHugh1, T. A. Seldon1,  
R. A. Brandon1, E. Sullivan2, J. J. Zimmerman2,3, M. Noursadeghi4,5 & R. B. Brandon1
The innate immune system of humans and other mammals responds to pathogen-associated molecular 
patterns (PAMPs) that are conserved across broad classes of infectious agents such as bacteria and 
viruses. We hypothesized that a blood-based transcriptional signature could be discovered indicating 
a host systemic response to viral infection. Previous work identified host transcriptional signatures 
to individual viruses including influenza, respiratory syncytial virus and dengue, but the generality 
of these signatures across all viral infection types has not been established. Based on 44 publicly 
available datasets and two clinical studies of our own design, we discovered and validated a four-gene 
expression signature in whole blood, indicative of a general host systemic response to many types of 
viral infection. The signature’s genes are: Interferon Stimulated Gene 15 (ISG15), Interleukin 16 (IL16), 
2′,5′-Oligoadenylate Synthetase Like (OASL), and Adhesion G Protein Coupled Receptor E5 (ADGRE5). 
In each of 13 validation datasets encompassing human, macaque, chimpanzee, pig, mouse, rat and all 
seven Baltimore virus classification groups, the signature provides statistically significant (p < 0.05) 
discrimination between viral and non-viral conditions. The signature may have clinical utility for 
differentiating host systemic inflammation (SI) due to viral versus bacterial or non-infectious causes.
Systemic inflammation (SI), as indicated by clinical signs such as fever and increased respiratory and heart rates, 
can be due to a variety of underlying non-infectious or infectious causes including trauma, thermal burns, sur-
gery, ischemia-reperfusion events and viral or bacterial infections. Patients presenting with SI can pose a diag-
nostic challenge for clinicians in determining the underlying etiology; consequently it can be difficult to select the 
most appropriate options for treatment and patient management1–5. There is a clinical need for rapid diagnostic 
tests that can help clinicians distinguish between non-infectious, viral and bacterial etiologies of SI in (critically 
ill) patients. Without such tests, patients may be over-prescribed antibiotics when there is little clinical evidence 
of infection4, 6. Reducing inappropriate and unnecessary use of antibiotics, the concept of antibiotic stewardship, 
is essential in slowing the spread of resistant bacteria7.
Traditional reference methods for determining bacterial or viral causes of SI involve the culture, isolation 
and identification of causative pathogens from multiple specimens from a patient. Such an approach, however, 
has several limitations: (i) the causative pathogen might not be present in the specimens taken for examination; 
(ii) the specimens may become contaminated by organisms unrelated to the cause of infection; (iii) multiple 
organisms may be present in the specimens (e.g. due to contamination or non-harmful microbiota) and it can 
be difficult to determine which organism is the cause of the presenting clinical signs8–10. Furthermore, (iv) some 
sampling techniques (e.g. bronchoalveolar lavage, lumbar puncture) are relatively invasive. Finally, (v) some path-
ogens are not easily cultured. Although traditional culture-based methods are steadily being supplemented or 
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displaced by immunological and molecular methods such as rapid immunoassays and polymerase chain reaction 
(PCR)11, 12, these newer methods also suffer from limitations, for example: (i) an inability to detect organisms not 
represented in an immunoassay or PCR panel; (ii) an inability to discriminate between live and dead organisms 
in a specimen; and (iii) a tendency to detect low levels of virus that may not be clinically relevant13.
Given these limitations, increasing attention is being paid to an alternative approach: that of identifying bio-
markers that reflect the differential host response to underlying non-infectious, bacterial, or viral conditions14–23. 
Our current investigation builds upon and extends previous host biomarker studies by identifying a molecular 
signature that is demonstrably specific to SI caused by a broad range of pathogenic viruses that represent all seven 
Baltimore virus classification groups and that cause infection in different tissues in multiple mammalian species. 
We used, as a discriminating function, the Area Under Curve (AUC) in Receiver Operating Characteristic Curve 
(ROC) analysis, and boosted specificity by employing a filtering step in our discovery process whereby biomark-
ers with high AUCs for non-viral causes of SI were removed. Independent validation of the signature in adult and 
pediatric cohorts demonstrated a strong discrimination of viral vs. non-viral causes of SI. Notably, this viral sig-
nature relies on only four biomarkers, and this high degree of parsimony should help to ensure the performance 
robustness necessary for effective translation to a rapid point-of-care format.
Results
Discovery of the pan-viral signature. An initial search was conducted across 13 Gene Expression 
Omnibus (GEO) datasets (Table 1) from human adult and pediatric subjects, and one GEO dataset from 
macaques. These 14 discovery datasets (comprising 417 cases and 182 controls) spanned three Baltimore Group 
I viruses (cytomegalovirus, human herpesvirus 6, enterovirus), one Group III virus (rotavirus), two Group IV 
viruses (Dengue, hepatitis C), and six Group V viruses (influenza, Lassa virus, rhinovirus, lymphocytic cho-
riomeningitis virus, respiratory syncytial virus, and measles virus). Next, a comprehensive, stepwise filter-
ing approach was applied to 19 additional GEO datasets comprising a total of 1337 cases and 1106 controls 
(Table 1), to exclude genes that were differentially expressed in conditions that may present as SI but appear 
unrelated to viral systemic inflammation. The end result, after the filtering step was applied, was a “pan-viral” 
signature based on the expression levels of four genes: Interferon Stimulated Gene 15 (ISG15), Interleukin 16 
(IL16), 2′,5′-Oligoadenylate Synthetase Like (OASL), and Adhesion G Protein Coupled Receptor E5 (ADGRE5). 
Table 2 summarizes what is known about the role, function and tissue expression of these four genes. Three of the 
genes (ISG15, OASL, IL16) have previously been reported to be associated with host response to viral infection, 
although they are not entirely specific to such a response. The four genes are all strongly expressed in whole blood 
and white blood cells, and to a lesser degree in most other tissues.
Validation of the pan-viral signature in independent GEO datasets. To ensure the resulting 
pan-viral signature was not overfit to the discovery datasets and was generalizable across different viruses and 
mammalian species, we next validated its performance in 13 human and non-human mammalian datasets (11 
from GEO and 2 from clinical trials, comprising a total of 332 cases and 302 controls). Importantly, these datasets 
represented a completely independent set of observations to those used during the discovery process. The vali-
dation datasets were chosen on the basis of (i) coverage of all seven of the Baltimore virus classification groups, 
and (ii) the potential impact of each virus on human health. In the case of the human datasets, the subjects had 
either naturally acquired viral infections, or had been vaccinated with attenuated viral vaccines (see Table 3 for 
details). The AUCs for performance of the pan-viral signature in the validation datasets ranged from 0.90 to 0.98.
GEO Validation Dataset #1: Adenovirus (Baltimore Group I, double-stranded DNA). Fifty-one different serotypes 
of adenovirus are known to infect humans, and serotypes 1, 2, 3, 4, 5, 7, 21 in particular are significant causes of 
upper respiratory tract infections, especially in children24–27. For evaluation of the performance of the pan-viral 
signature in Baltimore Group I viral infections, we chose GEO dataset GSE4128 which was derived from a study28 
of mice injected with adenovirus type 5 capsids (“vector”) or phosphate buffered saline (“mock”) (Fig. 1A). 
Adenovirus capsids are known to induce an innate inflammatory response28. Gene expression analyses were per-
formed on liver samples taken six hours post-infection for both wild type mice, and mice rendered deficient for 
complement component 3 (C3) by gene targeting. We observed a clear difference (AUC = 1.00) in pan-viral sig-
nature values between infected and mock-infected mice. Whilst the authors found a “blunted” immune response 
to adenovirus injection in the C3-deficient mice, we found little overall difference in pan-viral signature response, 
suggesting that the absence of C3 does not affect the pan-viral signature value. Note that for analysis of dataset 
GSE4128, our pan-viral signature incorporated the mouse gene 2′–5′ Oligoadenylate Synthetase-Like 1 (OASL1), 
which is the ortholog of human OASL29. Also, two samples were omitted from our analysis because the study 
authors labeled each sample as both ‘mock’ and ‘virus-infected’ in the phenotypic table associated with GSE4128.
GEO Validation Dataset #2: Porcine Circovirus PCV2 (Baltimore Group II, single-stranded DNA). There are few 
publicly available datasets, in either humans or other species, that describe host gene expression in response to 
infection by pathogenic Baltimore Group II viruses. Some example viruses in this group include parvoviruses 
(B19, canine parvovirus, bocavirus, adeno-associated virus) and circoviruses (porcine circovirus, chicken anemia 
virus). Porcine circovirus, type 2 (PCV2) is the primary cause of post-weaning multi-systemic wasting syndrome 
in pigs, which has had a large economic impact in the food production industry30. We analyzed a time-course 
dataset (GSE14790) derived from peripheral blood samples from Landrace cesarian-derived colostrum-deprived 
(CDCD) piglets infected, at post-gestation day 7, with subclinical doses of porcine circovirus 2 (PCV2, Burgos 
isolate). This study30 used an Affymetrix 24 K Genechip Porcine Genome Array to generate gene expression data. 
This microarray unfortunately did not include the OASL gene. We therefore were limited to analyzing this dataset 
using a linear combination of just two of the four genes, ISG15 and IL16, which carries most of the diagnostic 
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Study (Reference) Species Virus/Baltimore Group Cohorts/(Samples) Gender (M/F) Use AUC
GSE40366 (Reference #88) Human CMV/I Titer 0 (17) vs. Titer >20,000 (69) 0: 5/12 > 20,000: 12/57 Discovery (Core) 0.84
GSE51808 (Reference #89) Human Dengue/IV Healthy (9) vs. Acute (28) Healthy: 2/7 Acute: 20/8 Discovery (Core) 1.00
GSE52428 (Reference #18) Human Influenza/V Pre-challenge (37) vs. Symptomatics, early post-challenge (57) Pre: 11/9 Post: 11/9 Discovery (Core) 0.93
GSE41752 (Reference #90) Macaque Lassa/V Pre-challenge (11) vs. Post-challenge (9), Days 2, 3, 6 Male and female Discovery (Core) 1.00
GSE6269 (Reference #70) Human (pediatric) Influenza/V Healthy (6) vs. Influenza (18) Healthy: 5/1 Influenza: 10/8 Discovery (Sensitivity) 0.98
GSE40396 (Reference #17) Human HHV6/I Enterovirus/I Rhinovirus/V Control (18) vs. Infected (35) Control: 13/5 Infected: 19/16 Discovery (Sensitivity) 0.82
GSE40012 (Reference #16) Human Influenza/V Healthy (18) vs. Influenza (8) Healthy: 6/12 Influenza: 3/5 Discovery (Sensitivity) 1.00
GSE18090 (Reference #91) Human Dengue/IV Uninfected febrile (8) vs. Infected febrile (17)
Uninfected: 4/4 Infected: 
7/10 Discovery (Sensitivity) 0.79
GSE30550 (Reference #92) Human Influenza/V
Pre-challenge (8) vs. Post-challenge 
(61) Note: only the symptomatic 
patients were analyzed. For the 
post-challenge timepoints, only the 
timepoints between 21–69 hours were 
considered.
Information not available Discovery (Sensitivity) 0.95
GSE40224 (Reference #93) Human Hepatitis C/IV Healthy (6) vs. Infected (10) Healthy: 5/1 Infected: 10/0 Discovery (Sensitivity) 0.86
GSE5790 (Reference #94) Macaque LCMV/V Pre-challenge (11) vs. Post-challenge (11) Time course Not stated Discovery (Sensitivity) 0.64
GSE34205 (Reference #95) Human (pediatric) Influenza/V RSV/V Healthy (22) vs. Influenza (28) RSV (51)
Healthy: 14/8 Influenza: 
13/15 RSV: 24/27 Discovery (Sensitivity) 0.83
GSE5808 (Reference #96) Human (pediatric) Measles/V Healthy (3) vs. Infected (5) Healthy: 2/1 Infected: 3/2 Discovery (Sensitivity) 0.87
GSE2729 (Reference #97) Human (pediatric) Rotavirus/III Healthy (8) vs. Infected (10) Healthy: not stated Infected: 3/5 Discovery (Sensitivity) 0.99
GSE33341 (Reference #98) Human N/A Healthy (43) vs. Bacteremia (49) Healthy: 23/20 Bacteremia: 28/21 Discovery (Specificity) 0.79
GSE40366 (Reference #88) Human N/A Nonagenarian (6) vs. Young (11) Nonagenarian: 2/4 Young: 3/8 Discovery (Specificity) 0.71
GSE42834 (Reference #99) Human N/A
Healthy (113) vs. TB (35) Active 
sarcoidosis (39) Lung cancer (16) 
Bacterial pneumonia (14)
Healthy: (41/72) TB: (19/16) 
Sarcoidosis: (15/22, with 
2 not stated) Lung cancer: 
(10/6) Pneumonia: (9/5)
Discovery (Specificity) 0.76
GSE25504 (Reference #100) Human (neonate) N/A Healthy (26) vs. Sepsis (25) Healthy: 17/9 Sepsis: 13/12 Discovery (Specificity) 0.63
GSE30119 (Reference #101) Human (pediatric) N/A Healthy (44) vs. Sepsis (99) Healthy: 23/21 Sepsis: 54/45 Discovery (Specificity) 0.52
GSE17755 (Reference #102) Human N/A Healthy (53) vs. Autoimmunity (191) Healthy: 29/24 Autoimmunity: 39/152 Discovery (Specificity) 0.76
GSE19301 (Reference #103) Human N/A Asthma quiet (292) vs. Asthma exacerbation (117) 64.4% female Discovery (Specificity) 0.63
GSE38485 (Reference #104) Human N/A Healthy (22) vs. Schizophrenia (15) Healthy: 16/6 Schizophrenia: 11/4 Discovery (Specificity) 0.676
GSE36809 (Reference #105) Human N/A Healthy (37) vs. Blunt trauma (first 12 hours (150))
Healthy: 20/17 Trauma: 
94/56 Discovery (Specificity) 0.53
GSE46743 Unpublished Human N/A Dexamethazone Pre-dose (160) vs. Post-dose (160) All males Discovery (Specificity) 0.58
GSE61672 (Reference #106) Human N/A Anxiety Controls (179) vs. Patients (157)
Controls: 70/109 Patients: 
43/114 Discovery (Specificity) 0.57
GSE16129 (Reference #107) Human N/A Healthy (10) vs. S aureus sepsis (46) Healthy: 5/5 Sepsis: 29/17 Discovery (Specificity) 0.54
GSE40012 (Reference #16) Human N/A Healthy (18) vs. SIRS (12) Healthy: 6/12 SIRS: 10/2 Discovery (Specificity) 0.57
GSE40396 (Reference #17) Human (pediatric) N/A Controls (22) vs. Bacteremia (8) Controls: 15/7 Bacteremia: 6/2 Discovery (Specificity) 0.49
GSE6269 (Reference #70) Human (pediatric) N/A Healthy (6) vs. Bacterial infection (73) Healthy: 1/5 Sepsis: 41/32 Discovery (Specificity) 0.61
GSE35846 (Reference #108) Human N/A Gender: Men (65) vs. Women (124) 65/124 Discovery (Specificity) 0.57
GSE35846 (Reference #108) Human N/A Race: Caucasian (140) vs. African American (37)
Caucasian: 54/86 African-
American: 3/34 Discovery (Specificity) 0.50
GSE35846 (Reference #108) Human N/A Body fat: 9–30% (80) vs. 31–53% (109) 53/27 vs. 12/97 Discovery (Specificity) 0.47
GSE35846 (Reference #108) Human N/A Age: 26–60 (161) vs. 61–79 (28) 54/107 vs. 11/17 Discovery (Specificity) 0.50
Table 1. Discovery datasets used in this study. Details of datasets used for discovery of the pan-viral signature 
are listed including: an associated reference (if available), species studied, virus types represented, cohorts 
compared and the number of samples in each, gender numbers, how the dataset was used, and the performance 
(AUC) of the pan-viral signature in the cohorts described. Sample type analyzed was blood for all datasets in 
this table.
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power of the signature. Figure 1B shows box and whisker plots for ISG15/IL16 performance on weekly whole 
blood samples out to 29 days post-inoculation in piglets infected with PCV2. The ISG15/IL16 component of the 
pan-viral signature produced AUC = 0.94 for day 7 vs. day 0 comparison, and AUC = 1.00 for days 14, 21, 29 vs. 
day 0 comparison.
GEO Validation Dataset #3: Rotavirus (Baltimore Group III, double-stranded RNA). Rotaviruses are the most 
common cause of gastroenteritis worldwide in children less than five years of age, resulting in over 2 million 
hospitalizations annually31. Despite the main clinical signs of rotavirus infection being related to gastroenteritis, 
peripheral blood gene expression changes associated with infection have been reported32. We analyzed dataset 
E-GEOD-50628, generated from peripheral blood samples from six children with rotavirus infections in the acute 
phase (2–4 days from disease onset) versus recovery phase (7–11 days from disease onset)32. Figure 2 shows a box 
and whisker plot demonstrating that the pan-viral signature can be used to differentiate between children acutely 
infected with rotavirus from those in recovery (p < 0.05 by Mann-Whitney-U test).
GEO Validation Dataset #4: Yellow Fever Virus (Baltimore Group IV, positive-sense single-stranded RNA). The 
flaviviridae family includes yellow fever, dengue, hepatitis C, Japanese encephalitis and Zika virus which 
together impact the lives of millions of people33. Yellow fever virus is considered to be a prototypical flavivirus, 
for which single-dose vaccination with a live attenuated virus is an effective protection34. We analyzed GEO 
dataset GSE13699 from a yellow fever vaccination study35 in which two geographically separated groups of vol-
unteers (Lausanne, n = 11; Montreal, n = 15) were vaccinated subcutaneously on day 0 with Stamaril vaccine 
(Sanofi-Pasteur YF17D-204 YF-VAX), a vaccine containing live attenuated yellow fever virus that confers protec-
tion from 10 days following vaccination. Whole blood samples were collected on days 0, 3 and 7 for the Lausanne 
cohort and on days 0, 3, 7, 10, 14, 28 and 60 for the Montreal cohort. The pan-viral signature value peaked on day 
7 following vaccination and dropped to pre-vaccination levels by day 14 (Fig. 3). The temporal behavior of the 
pan-viral signature suggests that the vaccine engenders an immune response that peaks on day 7 but does not 
persist beyond day 14 (as might be expected for the response to an attenuated vaccine).
GEO Validation Dataset #5: Respiratory Syncytial Virus (Baltimore Group V; negative-sense single-stranded 
RNA). The most common cause of acute lower respiratory infection in children less than five years of age is 
respiratory syncytial virus (RSV), with an estimated 3.4 million infected children requiring hospitalization each 
year worldwide36. We analyzed GEO dataset GSE69606, which was generated in a study designed to identify 
biomarkers of RSV infection severity in children37. In this study, peripheral blood samples were collected from 
children with mild (n = 9), moderate (n = 9) or severe (n = 8) clinical signs during the acute stage of infection. An 
additional set of samples was collected 4–6 weeks later from recovered children who originally displayed mod-
erate or severe clinical signs. The pan-viral signature score showed a clear difference between acute and recovery 
stages (AUC = 0.903), but was invariant in the acute stage regardless of RSV infection severity (Fig. 4).
GEO Validation Dataset #6: HIV-1 Virus (Baltimore Group VI, positive-sense single-stranded RNA virus, replicat-
ing through a DNA intermediate). The initial clinical signs of acute HIV-1 infection are relatively non-specific, 
involving fever and influenza-like illness, which bear a clinical resemblance to other types of infection including 
bacterial sepsis. We analyzed GEO dataset GSE29429 which was generated from a time-course study38 com-
paring (A) HIV-1 infected adults who first presented in the acute stage of infection but who did not receive 
antiretroviral therapy (ART; African, n = 43), versus (B) HIV-1 infected adults who presented similarly but did 
receive ART (USA, n = 15). The study also included two sets of matched healthy controls (n = 55). Blood samples 
were collected at study enrollment when the patients had a confirmed acute infection, and at post-enrollment 
weeks 1, 2, 4, 8, 12 and 24. Figure 5 shows AUCs over time for the pan-viral signature when comparing the 
Gene Role/Function/Tissue Expression References
ISG15 Interferon-stimulated gene 
15; Ubiquitin-like modifier
Key role in innate immune response to viruses including influenza, 
HIV-1 and Ebola. Induces gamma interferon and natural killer cell 
proliferation. Chemotactic for neutrophils. Strongly expressed in EBV-
transformed lymphocytes.
HGNC Symbol: ISG15 
OMIM: 14751, #616126 
References #109–112
IL16 Interleukin-16
Pleiotropic cytokine that functions as a chemoattractant, a modulator of 
T cell activation, and an inhibitor of HIV replication. Ligand for CD4. 
Strongly expressed in whole blood, brain, spleen and EBV-transformed 
lymphocytes. Upregulated in viral infections.
HGNC Symbol: IL16 OMIM: 
603035 References #59, 
113, 114
OASL 2′–5′-Oligoadenylate 
Synthetase-Like
Displays antiviral activity against encephalomyocarditis virus (EMCV) 
and hepatitis C virus (HCV) via an alternative antiviral pathway 
independent of RNase L. Can bind double stranded RNA. Strongly 
expressed in whole blood and EBV-transformed lymphocytes.
HGNC Symbol: OASL 
OMIM: 603281 References 
#52, 115, 116
ADGRE5 (CD97) Adhesion G 
Protein-Coupled Receptor E5
May play a role in cell adhesion as well as leukocyte recruitment, 
activation and migration. Contains multiple extracellular EGF-like 
repeats which mediate binding to chondroitin sulfate and the cell surface 
complement regulatory protein CD55. Strongly expressed in whole 
blood, spleen and arterial tissue.
HGNC Symbol: ADGRE5 
OMIM: 601211 References 
#117, 118
Table 2. RNA transcripts comprising the pan-viral signature. Details of the role, function and tissue expression 
of the underlying genes are provided along with associated references. ISG15, IL16 and OASL have previously 
been directly linked to an immune response to a virus infection.
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healthy controls to either the untreated African patients (panel A) or the treated American patients (panel B). The 
pan-viral signature AUC when comparing the untreated African patients to the corresponding healthy African 
controls remained at or above 0.9 at all time points; in contrast, the AUC when comparing the treated American 
patients to the corresponding healthy American controls dropped from above 0.9 at enrolment to less than 0.5 
by Week 24 (panel C). The decrease in pan-viral signature values in the treated American patients also reflected 
a corresponding decrease in mean HIV-1 viral loads from ~800,000 virus particles/mL blood at study entry to 
~2,000 virus particles/mL blood by week 24.
GEO Validation Dataset #7: Hepatitis B (Baltimore Group VII, double-stranded DNA virus, replicating through a 
single-stranded RNA intermediate). We analyzed GEO dataset GSE68112 which was generated from a study 
of HBV infection of primary rat hepatocytes39. Figure 6 shows pan-viral signature scores over a 72-hour period 
in primary rat hepatocytes. In this study, primary rat hepatocytes were plated at 0 hours, then infected with an 
adenovirus-based construct containing either the gene for Green Fluorescent Protein (GFP) alone, or a copy 
of the Hepatitis B Virus (HBV) genome in combination with the GFP gene. Post-infection, an increase in the 
pan-viral signature score was observed in rat hepatocytes infected with the adenovirus + GFP + HBV construct, 
compared to infection with the adenovirus + GFP construct lacking HBV. At the 48 hour timepoint, this increase 
Study (Reference) Species
Virus/Baltimore 
Group Cohorts/(Samples) Gender (M/F) Use AUC or p-value
GSE4128 (Reference #28) Mouse1 (liver) Adenovirus/I
Mock (6 knockout, 5 wild-type) 
vs. Vector-injected (11 knockout, 
5 wild-type)
Not stated Validation 1.00
GSE14790 (Reference #30) Pig Porcine circovirus, type 2 Uninfected (4) vs. Infected (4) Not stated Validation
0.94 (day 7 vs. day 
0); 1.00 (days 14, 21, 
29 vs. day 0)
E-GEOD-50628 
(Reference #32) Human Rotavirus/III Acute (6) vs. Recovery (6) 4/2 Validation p < 0.05
2
GSE13699 (Reference #35) Human Yellow fever (attenuated)/IV
Pre-vaccination (26) vs. Post-
vaccination Days 3/7 (51) Time 
course
14/12 Validation 0.98
GSE69606 (Reference #37) Human (pediatric) RSV/V Mild (9), Moderate (9), Severe (8) vs. Follow-up (17)
Mild: 6/3 
Moderate: 8/1 
Severe: 6/2 
Follow-up: 14/3
Validation 0.90
GSE29429_GPL6947 
GSE29429_GPL10558 
(Reference #38)
Human HIV/VI Healthy (55) vs. Infected (58) at study entry
Healthy:31/24 
Infected: 41/17 Validation 0.91
GSE68112 (Reference #39) Rat (primary hepatocytes)
Adenovirus/I 
Hepatitis B/VII
Uninfected (6) vs. Infected 
with adenovirus construct (3) 
vs. infected with adenovirus/
hepatitis B construct (3) at 48 
and 72 hours; Time course
Tissue culture Validation p > 0.05 at 48 hours; p < 0.02 at 72 hours3
GSE67059 (Reference #21) Human (pediatric) HRV/IV HRV- (37) vs. HRV + (114) HRV−: 21/16 HRV+: 76/38 Validation 0.90
GSE57384 (Reference 
#119) Mouse
1 Influenza/V Pre-challenge (30) vs. Post-challenge (30) Time course Not stated Validation 1.00
4
GSE22160 (Reference #14) Chimpanzee (liver biopsy)
Hepatitis E/IV 
Hepatitis C/IV
Pre-HEV (3) vs. Post-HEV (3) 
Time course; Pre-HCV (4) vs. 
Post-HCV (4) Time course
Not stated Validation 1.00; 1.00
GSE58287 (References 
#120, 121) Macaque Marburg/V
Pre-challenge (15) vs. Post-
challenge (15) Time course All female Validation 0.98
FEVER (This paper) Human (adults)
Varicella/I 
Epstein-Barr/I 
CMV/I Influenza/V 
Dengue/IV
Bacterial infection (55) vs. 
Viral infection (15); Viral 
infection (15) vs. Uninfected 
(22); Bacterial infection (55) vs. 
Uninfected (22)
44/48 Validation 0.93; 0.85; 0.58
GAPPSS (This paper) Human (pediatric)
Rhinovirus/IV 
Enterovirus/I 
Coronavirus/IV 
Parainfluenza/V 
RSV/V
Sepsis (25) vs. Viral SI (5); 
Sepsis + Viral SI (10) vs. Viral 
SI (5); Sepsis + Viral SI (10) vs. 
Sterile SIRS (29); Sterile SIRS 
(29) vs. Sepsis ± Viral SI (35); 
Sterile SIRS (29) vs. Viral SI (5); 
Sepsis vs. sterile SIRS
25/26 Validation 0.76; 0.70; 0.64; 0.62; 0.91; 0.60
Table 3. Validation datasets used in this study. Details of datasets used for validation of the pan-viral signature 
are listed including: an associated reference (if available), species studied, virus types represented, cohorts 
compared and the number of samples in each, gender numbers, how the dataset was used, and the performance 
(AUC) of the pan-viral signature in the cohorts described. Sample type analyzed was blood unless otherwise 
noted in the Species column. 1The mouse ortholog OASL1 of the human gene OASL was used in the analysis 
of mouse GEO datasets. 2Mann-Whitney U test. 3One-tailed t-test, assuming unequal variances between the 
two comparison groups. 4Pan-viral signature AUC evaluated over days 2–6 post-infection, compared to pre-
infection state (GSE57384).
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was small and not statistically significant (p > 0.05 by one-tailed t-test, unequal variances assumed). However, at 
72 hours post-infection, the increase was much larger and statistically significant (p < 0.02 by one-tailed t-test, 
unequal variances assumed). The results at 72 hours post-infection indicate that the pan-viral signature responds 
to acute infection by HBV in rats, in tissues other than blood, in an in vitro study.
In Figs 1–6 we have presented validation data representing all seven Baltimore viral classification groups. In 
Supplementary Figures S1–S5 we discuss additional GEO datasets, derived from human and animal peripheral 
blood samples, which were used to further validate the pan-viral signature. Human studies included rhinovi-
rus (HRV) infection in children (Figure S1; Baltimore group IV; AUC 0.81-0.90); and a time-course study in 
which adult volunteers were inoculated with influenza virus (Figure S2; Baltimore Group IV; AUC up to 1.00). 
Animal studies included a time-course study of influenza in mice (Figure S3; Baltimore group IV; AUC up to 
Figure 1. Pan-viral signature in models of infection involving DNA viruses. Panel (A): Adenovirus (double-
stranded DNA; Baltimore group I). Pan-viral signature measured in liver tissue derived from wild-type or 
C3-knockout mice injected with phosphate buffered saline (mock) or adenovirus type 5 capsids (vector), from 
dataset GSE4128. The box and whisker plots show the median and interquartile range for each group. The pan-
viral signature produced AUC = 1.00. Panel (B): Porcine circovirus (single-stranded DNA; Baltimore group II). 
Dataset GSE14790 was generated from samples of peripheral blood, drawn weekly from four Landrace CDCD 
piglets infected with subclinical doses of PCV2 (Burgos isolate) at day 7 post-gestational age and followed for 29 
days. The OASL gene was not available on the microarray, so only the ISG15/IL16 component of the pan-viral 
signature is shown here, in a box-and-whisker plot of median and interquartile range for four individual piglets 
at different days post-inoculation. The ISG15/IL16 component of the pan-viral signature produced AUC = 0.94 
for day 7 vs. day 0 comparison, and AUC = 1.00 for days 7, 14, 21, 29 vs. day 0 comparison.
Figure 2. Pan-viral signature scores for children with rotavirus infection. Box and whisker plots showing 
pan-viral signature scores in peripheral blood for six children in the acute versus recovery stages of rotavirus 
infection (E-GEOD-50628). The pan-viral signature produced AUC = 0.86.
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1.00), which parallels the aforementioned human study; inoculation of Hepatitis C and Hepatitis E in chimpan-
zees (Figure S4; Baltimore group IV; AUC 0.96-1.00); and infection of macaque monkeys with Marburg virus 
(Figure S5; Baltimore group V; AUC 0.98). Performance of the pan-viral signature was strong in all of these addi-
tional validation datasets, as indicated in Table 3 and in the Supplementary Figures.
Figure 3. Time-course of pan-viral signature score for human volunteers vaccinated with live attenuated yellow 
fever vaccine. Box and whisker plot of the pan-viral signature values for 26 human volunteers vaccinated with 
Stamaril and followed for up to 60 days (GEO dataset GSE13699). The pan-viral value increased from day 3 
post-vaccination and peaked on day 7. By day 14 the value had returned to pre-vaccination levels.
Figure 4. Pan-viral signature score for children with acute RSV infection and following recovery. Box and 
whisker plots for dataset GSE69606. Panel (A): pan-viral signature for children with acute RSV infection. 
Panel (B): pan-viral signature for moderately and severely affected children in recovery (4–6 weeks later). 
AUC = 0.903 for the difference between acute and recovery datasets. Abbreviation: Mod, moderate.
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Additional validation from clinical studies. The pan-viral signature was also tested in two clinical stud-
ies that were conducted to determine the signature’s ability to differentiate patients with virus-associated SI from 
those with SI due to other etiologies, including bacterially- and surgically-induced SI. Gene expression levels were 
inferred from RNA sequencing (RNA-seq) data obtained from whole blood samples collected in PAXgene blood 
RNA tubes.
Internal Validation Dataset #1: FEVER study. This study involved adult patients presenting to a UK emergency 
department with fever (see the Supplementary Text S1, Figure S6 and Table S1 for study details, and Table S2 
for line data). All patients included in the study were admitted to hospital and received retrospective physician 
diagnosis (RPD), using all available clinical information at discharge, including any results of clinical microbi-
ology and virus testing, to determine the presumptive etiology of the fever. Of the 90 patients comprising the 
FEVER study cohort, those with confirmed bacterial infections (N = 54) were identified by microbial culture 
of pathogenic bacteria from sterile sites. Confirmed viral infections (N = 14) were identified by positive nucleic 
acid detection or serological tests as ordered by the attending clinician (see Text S1). Patients who had no posi-
tive microbiological tests and recovered without empirical antimicrobial treatment (N = 22) were designated as 
indeterminate cases. Positively identified viruses in the ‘virally infected’ patients included Baltimore group I (her-
pes virus, varicella-zoster virus, Epstein-Barr virus, cytomegalovirus), Baltimore group IV (dengue virus), and 
Baltimore group V (Influenza A and B viruses). Figure 7, panel A shows box and whisker plots of the pan-viral 
signature, assayed in blood samples from the three patient groups. The pan-viral signature effectively separated 
febrile patients of confirmed viral etiology from those of confirmed bacterial etiology with AUC 0.93. All patients 
Figure 5. Pan-viral signature AUCs for patients with acute HIV-1 infection compared to matched uninfected 
healthy subjects (GEO dataset GSE29429). Panel (A): Pan-viral signature score for healthy African controls 
(solid points) versus HIV-1 -positive untreated African subjects (open points). Panel (B): Pan-viral signature 
score for healthy American controls (solid points) versus HIV-1 -positive ART-treated American subjects (open 
points). Panel (C): When untreated African patients were compared to the corresponding healthy African 
controls, the pan-viral signature AUC (±95% CI) remained at or above 0.9 for all timepoints (red diamonds). 
In contrast, when American patients receiving ART-treatment were compared to the corresponding American 
controls, the pan-viral signature AUC dropped from above 0.9 at enrolment to less than 0.5 by week 24 (blue 
triangles). Abbreviations: ROC, receiver operating characteristic curve; ART, anti-retroviral therapy; AUC, area 
under curve.
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in this study had a fever (temperature >38.5 °C) at the time of presentation and blood sampling. The fact that the 
indeterminate cases recovered spontaneously may be most consistent with self-limiting viral illnesses, but inter-
estingly only 2–3 of 22 indeterminate cases had pan-virus signature scores significantly higher than the proven 
cases of bacterial infection, suggesting that the majority of these indeterminate cases did not represent acute viral 
infections.
Internal Validation Dataset #2: GAPPSS study. A second clinical study40 (clinicaltrials.gov reference # 
NCT02728401) was undertaken that involved pediatric patients (age range: 38 weeks estimated gestational 
age – 18 years) in intensive care (see Supplementary Text S2 and Table S3 for study details, and Table S4 
for line data). Using all available clinical information, including clinical microbiology and virus testing, the 
patients were retrospectively diagnosed with bacterial sepsis (n = 25), bacterial sepsis with a viral coinfec-
tion (n = 10), viral SI (n = 5), or sterile post-surgical SI (n = 29). Testing of respiratory samples from the 
cohort, using the BioFire FilmArray Respiratory Panel (Biofire Diagnostics, Utah, USA), identified viruses in 
Baltimore group I (varicella-zoster virus; herpes simplex virus), Baltimore group IV (rhinovirus/enterovirus; 
coronavirus HKU1; norovirus Type 2) and Baltimore group V (parainfluenza 3; respiratory syncytial virus; 
metapneumovirus). Results are displayed graphically in Fig. 7, Panel B and summarized in Table 3.Whilst only 
a limited number of viral patients were included in this study (n = 5), the pan-viral signature resolved viral 
SI from non-infectious SI with AUC 0.91, and resolved viral SI from bacterial sepsis with AUC 0.76. Similar 
to our observation in the adult study (Fig. 7, panel A above), the pan-viral signature was much less effective 
at separating bacterial sepsis from non-infectious SI (AUC 0.60) demonstrating that the signature is specific 
for viral systemic inflammation and not bacterial systemic inflammation. Discordance between RPD and the 
pan-viral score in some cases suggests the possibility that either some patients had undetected viral infections, 
that the pan-viral signature had reduced specificity in children, or the study was not sufficiently powered to 
draw definitive conclusions.
Figure 6. Pan-viral signature scores in primary rat hepatocytes infected with an adenovirus vector containing 
GFP, or GFP plus Hepatitis B virus. Box-and-whisker plots for the pan-viral signature score over time course 
of infection in primary rat hepatocytes (GEO dataset GSE68112). Primary rat hepatocytes were plated at 
0 hours, and then infected with an adenovirus vector (Control), the adenovirus vector fused to a gene for Green 
Fluorescent Protein (Adeno+GFP), or the adenovirus vector fused to both the Green Fluorescent Protein gene 
and a copy of the Hepatitis B Virus genome (Adeno+GFP+HBV). Panel (A): response after 48 hours. Panel (B): 
response after 72 hours.
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Resolution of viral vs. bacterial SI using two specific signatures. We have previously discovered and 
validated a four-gene host response signature (SeptiCyteTM LAB) for differentiating SI due to either bacterial or 
non-infectious etiology41. Given that the pan-viral signature was developed to be specific for discrimination of 
viral vs. non-infectious SI, and appears to be largely unaffected by bacterial infection, we hypothesized it would be 
possible to apply the two signatures simultaneously to allow a three-way discrimination between non-infectious 
SI, viral SI, and bacterial SI.
As an initial test of this hypothesis, we reanalyzed a dataset (GSE63990) from a study42 of patients with acute 
respiratory illness (ARI). This study enrolled 273 patients of which 115, 70 and 88 received retrospective clinical 
diagnoses of bacterial infection, viral infection, and non-infectious illness, respectively. We analysed GSE63990 
using an 8-gene classifier consisting of the four pan-viral signature genes (IL16, ISG15, OASL, ADGRE5) com-
bined with the four genes (CEACAM4, LAMP1, PLA2G7, PLAC8) from SeptiCyteTM LAB. The line data used 
in our analysis is given in Supplementary Table S5. We applied a Random Forest - multidimensional scaling 
(RF-MDS) analysis43–45 using the combined eight genes. Figure 8 (Panels A, B) presents two different visual rep-
resentations of the analysis, which show that the GSE63990 dataset has been resolved into the three patient sub-
groups of bacterial infection (green), viral infection (purple), and non-infectious illness (orange). An animated 
representation of this analysis, in which the figure is rotated in three dimensions, is provided in Supplementary 
Animation S1. To assess whether these 8 genes were contributing materially to the underlying biology, and thus 
to the clinical diagnoses of viral, bacterial or non-infectious illness, we used the resampling method described 
by Li et al.46 and created 2,000 permutations of GSE63990 in which the group labels were randomly shuffled. 
Application of the Random Forest model to the permuted datasets failed to resolve the three groups, after group 
label randomization. Thus the classifier was found to be significant under the null hypothesis. That is, the results 
presented in Fig. 8 illustrate a true dependency between the 8 genes and the response labels, at a significance level 
of p < 0.001. Additional details of the permutation test are provided in Supplementary Figures S7 and S8.
We note the GSE63990 dataset was not used in the initial discovery or validation of either the pan-viral signa-
ture or SeptiCyteTM LAB signature. Also, the possibility of bacterial or viral co-infection was not considered in our 
analysis. Furthermore, the diagnostic performance of SeptiCyteTM LAB and the pan-viral signature is dependent 
upon the accuracy of retrospective physician diagnoses of acute respiratory illness cases. There is some degree 
of discordance between the retrospective physician diagnoses and our two signatures, a finding that was also 
reported in the original publication42 when classifiers reported in that paper were used (35 of 273 patients had a 
discordant result (12.8%)). Clearly further validation work is required to demonstrate the clinical utility of com-
bining both signatures, but these data provide a valuable insight into the potential of an assay that combines viral 
and bacterial host responses.
Discussion
In this paper we identify and validate a peripheral-blood signature based on the expression of four genes (ISG15, 
OASL, IL16, ADGRE5), which exhibits high AUC for discriminating viral from bacterial and non-infectious 
causes of SI. This signature has been validated using publicly available GEO datasets, and in our own clinical 
Figure 7. Pan-viral signature score in two clinical studies. Panel (A): Adult patients presenting to the 
emergency department with fever. Box and whisker plots for 90 patients in the FEVER study retrospectively 
diagnosed with bacterial sepsis (n = 54; red points), indeterminate status (Indet, n = 22; blue points), or viral 
infection (n = 14; green points). Panel (B): Pediatric intensive care patients. Box-and-whisker plot of pan-viral 
signature scores for 69 children retrospectively diagnosed as sepsis (n = 25), sepsis with an identified viral 
coinfection (Sepsis + Virus, n = 10), post-surgical systemic inflammation (Control, n = 29) and viral-associated 
systemic inflammation (Virus, n = 5).
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studies in adults and children. We have termed the signature “pan-viral” because it has demonstrable diagnostic 
power across six mammalian species (human, macaque, chimpanzee, pig, rat and mouse), in multiple tissue types, 
in vivo and in vitro, and in infections caused by viruses representing all seven Baltimore classification groups.
Because the direct sensing of different classes of viruses is mediated through different Pathogen-Associated 
Molecular Patterns (PAMPs), we hypothesize that the pan-viral signature most likely reflects some type of inte-
grated downstream response47, 48. A plausible hypothesis regarding the functional significance of three of the 
genes in the pan-viral signature (ISG15, OASL, IL16) is that they relate to type 1 interferon signaling. ISG15, a 
well-studied component of the type 1 interferon-mediated response to viral infection, is a mediator of ISGylation, 
a protein modification similar to ubiquination49–52. OASL is a non-enzymatic member of the highly conserved 
OAS gene family53 and is also a component of the Type 1 interferon response to viral infection54, 55. IL16 is a 
cytokine with multiple functions, having been linked to inhibition of HIV-1 infection56, 57, modulation of HBV 
infection58, lentiviral infection59 and autoimmune and allergic disorders60, 61. A paper from some years ago62 
demonstrated that IFN-α induces the secretion of IL-16 by several cell types. A more recent paper63 reported 
a negative effect of IFN-β1a (a type 1 interferon) on the expression level of IL-16; thus IL16 may also be func-
tionally related to the Type 1 interferon pathway, although the linkage is not especially well studied or docu-
mented. Finally, although ADGRE5 has not been linked to interferon Type 1 signaling, this gene has previously 
been directly associated with host response to infection by human papilloma virus64 and HIV65. Additionally, 
the ADGRE5 ligand DAF (decay accelerating factor) is the cellular receptor for both echovirus66, 67 and coxsackie 
virus68, 69.
Context for our work is found in prior studies describing transcriptional signatures that were designed to 
distinguish between some viral, bacterial, and non-infectious SI conditions. However, we have found that prior 
work was limited by either a large number of genes/probes required, a lack of specificity of the signatures in light 
of other possible causes of SI, or a lack of validation across a broad range of virus types. For example, Zaas et al.19  
identified a 30-gene signature from microarray analysis of symptomatic vs. asymptomatic subjects infected with 
rhinovirus, respiratory syncytial virus, or influenza A; this signature was able to discriminate symptomatic influ-
enza A-infected subjects from both healthy subjects and bacterially-infected subjects in a second independent 
cohort. Other researchers17, 18, 20, 70 have described signatures for discriminating between viral infections and 
other conditions, but with limitations relating to the large number of biomarkers in the signature (>18), a limited 
number of viruses examined, or a lack of demonstrated specificity with respect to possible bacterial co-infection 
or SI due to non-infectious causes. Tsalik et al.42 identified host gene expression signatures for viral, bacterial and 
non-infectious causes of acute respiratory inflammation. Whilst respiratory illness accounts for a large proportion 
of patients presenting to emergency clinics, the viral signature identified in this study consisted of a large number 
of genes (n = 33) and was not validated on patients with SI as a result of viral infection of body systems other than 
respiratory. Sweeney et al.22, 71 described an 11-gene signature for differentiating infectious and non-infectious SI, 
and also a 7-gene signature for differentiating bacterial and viral SI, but not non-infectious SI. Used in succession 
the authors claimed that such signatures could be used as an “integrated antibiotics decision model”. Finally, 
Herberg et al.23 described a two-gene signature for differentiating viral and bacterial infection in febrile children. 
This signature was developed without using a cohort of non-infectious SI and therefore the output is binary and 
assumes that patients have a viral or bacterial infection.
Figure 8. Resolution of patients with acute respiratory illness (ARI) into three clusters corresponding to 
bacterial infection, viral infection, and non-infectious illness (GSE63990). A cohort (GSE63990) having 
multiple types of pathogen infections has been analyzed using a Random Forest - multidimensional scaling 
(RF-MDS) process that combines the pan-viral signature and the SeptiCyteTM LAB signature41. Panel (A): 
A three-dimensional projection of points from an 8-dimensional space defined by the expression levels of 
the 8 individual genes comprising the two signatures. This projection was chosen to show maximal visual 
separation between the three clinical groups (bacterial, viral, and non-infectious illness). Panel (B): Another 
three-dimensional projection, chosen to show the relatively high dispersion of the virally infected samples. Key: 
bacterial, green points; viral, purple points; non-infectious illness, orange points.
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Our approach to discovery of host response viral biomarkers is novel in comparison to the prior studies 
because we have: (1) included representative pathogenic viruses from all seven Baltimore viral classification 
groups, thus providing evidence that innate immune response commonalities may be potentially harnessed for 
broad diagnostic utility across diverse viral infection; (2) incorporated datasets from multiple mammalian species 
to demonstrate the robustness that host response -based methods offer; (3) used non-infectious SI as our control 
group, recognizing the fact that discriminating viral, bacterial, and non-infectious causes of SI is a highly criti-
cal and difficult distinction to make on the basis of clinical features alone6, 41, 71, 72; (4) applied a comprehensive 
specificity screen to eliminate biomarkers that respond to potentially confounding medical conditions or demo-
graphic variables; and (5) applied strong selection pressure towards minimizing the number of biomarkers in the 
pan-viral signature to avoid overfitting and to enable a straightforward conversion to a practical assay format, 
such as a format employing reverse transcription - quantitative polymerase chain reaction (RT-qPCR).
A number of the discovery and validation datasets in our study (Tables 1 and 3 respectively) were derived 
from time course and/or challenge experiments. The use of such datasets is important because samples taken 
from subjects early in the viral pathogenesis, or from otherwise healthy subjects undergoing vaccine challenge, 
are most likely to reflect an infection with a single type of virus, rather than an infection with multiple virus types, 
or co-infection with bacteria. Analysis of the time-course datasets revealed that, in general, it took up to three 
days post-exposure for the pan-viral signature to first register a significant difference compared to pre-exposure 
samples; the pan-viral signature response coincided with the ability to first detect virus in tissue but preceded 
viremia, clinical signs and antibody response.
Our study has several limitations. First, the validation datasets we employed were generated from multiple 
sample types (blood, liver biopsy, cultured hepatocytes) using multiple experimental methods (microarrays, 
RNA-seq). This diversity of sample types and methods could contribute a significant amount of noise which 
would tend to obscure relevant signals. Once the assay has been translated to a single assay technology and sam-
ple type, then more precise comparisons between different viral infections and disease severities can be made. 
Second, Baltimore Group II is under-represented in our validation data. The dataset that we analyzed (GSE14790, 
porcine circovirus infection) did not include OASL. Because the genes comprising the pan-viral signature were 
discovered by a process in which gene pairs were linearly combined, we present results for the linear combination 
of ISG15 and IL16, which still carries significant diagnostic power in the cohort tested (GSE14790). We expect 
that eventually additional Baltimore group II datasets will become available, which will allow a more in-depth 
validation of the pan-viral signature performance in this viral group.
Third, the FEVER and GAPPSS studies we have described in Fig. 7 are limited with respect to the size of the 
viral infection groups (n = 14 for FEVER, and n = 5 for GAPPSS). These studies are ongoing, and additional 
recruitment is expected over the coming months.
Fourth, definitive clinical utility of the pan-viral signature remains to be determined. Our observations from 
a variety of validation datasets suggest that the pan-viral signature could potentially have multiple clinical appli-
cations: as an early diagnostic tool, in monitoring recovery from viral infections, in monitoring host response 
to therapeutic interventions, in monitoring host response to vaccines, and/or in surveillance of populations at 
risk. For example, in combination with a bacterial signature that has inherent high negative predictive value, 
the pan-viral signature could potentially be a useful tool in an antibiotic stewardship program, or in providing 
guidance for ongoing diagnostic testing. It could also prove useful in identifying patients early in the course of a 
viral infection, which in turn could affect decisions on infection control and patient isolation, especially in disease 
outbreaks. Additional clinical studies will be needed to determine if the pan-viral signature has clinical utility for 
these or other purposes.
We believe a particular strength of our discovery approach was the resultant specificity of the pan-viral sig-
nature when compared to bacterial and non-infectious causes of SI. Such specificity allows this signature to 
be combined with our SeptiCyteTM LAB signature, which has specificity for bacterial SI. The combination of 
virus-specific and bacteria-specific host SI signatures may provide clinicians with timely information to aid in 
informed decision making in patients presenting with SI, for example in deciding whether to initiate or cease 
antibiotics. Ultimately, clinical utility for a “pan-viral” signature may be found in combination with an infec-
tion status classifier, like that we have previously described40 whereby together, both the probability of systemic 
infection, along with infection type (i.e. bacterial vs. viral) can be rapidly determined and factored into patient 
management and treatment decisions.
Methods
Statistical Tests. Several different statistical tests were used to evaluate the performance of classifiers. (1) 
When sufficient numbers of samples were available, ROC curve analysis was performed and AUCs were calcu-
lated. A resampling method was used to estimate the AUC 95% confidence interval (CI) associated with each 
ROC curve. Venkatraman’s method73, as implemented in the pROC package in R, was used to compare the AUC 
values between different biomarker combinations with p < 0.05 considered statistically significant. (2) For some 
performance estimates the Mann-Whitney U test was used, which gives an equivalent statistic to AUC74. (3) 
For some analyses with very small sample sizes, Student’s t-test was used, following appropriate small-sample 
guidelines75.
Discovery of the pan-viral signature. In the discovery phase we searched for RNA transcripts or tran-
script combinations with expression levels that varied during a host response to viral infection. The initial 
search was conducted across 13 datasets from human adult and pediatric subjects, plus one set of data from 
macaques. We expected there to be some variability between datasets in quantification of the levels of particu-
lar RNA transcripts because different studies used different sample types, sample collection tubes, experimen-
tal platforms (microarrays, RNA-seq), and data reduction/processing methods to estimate gene expression 
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levels. A considerable literature has arisen on comparing gene expression results across platforms76–79 and on 
estimating the biases that may arise specifically within microarray-based approaches80, 81 and RNA-seq -based 
approaches82–84. For each GEO dataset, we represented each gene’s RNA transcript family by the single microarray 
probe that gave the maximal average intensity for that gene, across all samples used in the analysis. Probe identi-
ties are listed in Supplementary Table S6.
We began the search using four core datasets (GSE40366, GSE51808, GSE52428 and GSE41752). To decrease 
the dimensionality of the search space and to ensure that only those transcripts with moderate to high expression 
levels were examined, we applied a mean expression filter that allowed only the top 6,000 RNA transcripts from 
each of the core datasets to be retained. Regression analysis was then applied across the search space, with RNA 
transcripts combined in pairs, using a linear objective function with coefficients set to −1 or +1 for the log2 
expression value of each transcript in a pair. In theory, each core dataset produced 36,000,000 transcript pairs to 
examine (not taking into account reciprocal pairs). Setting the coefficients to −1 or +1 (instead of allowing the 
coefficients to vary) reduced the computational effort to a manageable level. ROC curve analysis on each tran-
script pair then allowed the transcript pairs to be ranked by AUC for their ability to separate the case and control 
groups in each of the core datasets.
The RNA transcript pairs were then filtered by the following two-step process: (1) those with average AUC 
<0.92 across the four core datasets were discarded; and (2) those with average AUC < 0.92 across ten additional 
viral-based “sensitivity” datasets (Table 1) were discarded. This resulted in a severely reduced pool of transcript 
pairs (N = 856) with AUC ≥ 0.92. Next, the four “core” and ten “sensitivity” datasets (Table 1) were individually 
normalized, as follows. (1) The mean expression level of each RNA transcript was calculated across all samples in 
that dataset. (2) The expression level of this transcript in each sample was then adjusted by subtracting its mean 
value. (3) All expression values were then scaled to unit variance. This procedure was performed for every tran-
script in each individual dataset. All 14 viral datasets were then merged into a single expression matrix.
Specificity screen with independent GEO datasets. To ensure that candidate transcript pairs 
were associated uniquely with a viral host response and not a host response due to confounding phenotypes, 
they were individually assessed against 19 “specificity” datasets. The specificity datasets were derived from 
bacterial-positive patients, some of whom were classified as septic (GSE3341, GSE16129, GSE40396), patients 
with SIRS (GSE40012), healthy subjects ranging in age from childhood to nonagenarian (GSE40366), patients 
with inflammation not associated with positive viral infection (GSE42834, GSE17755, GSE19301, GSE47655, 
GSE38485, GSE36809, GSE29532, GSE61672), neonatal and pediatric bacterial sepsis patients (GSE25504, 
GSE30119, GSE6269), patients with anxiety (GSE61672), subjects administered dexamethasone (GSE46743), and 
healthy subjects displaying demographic confounders such as age, ethnicity and gender (GSE35846). Candidate 
transcript pairs having AUC >0.80 in more than 3 of the 19 specificity datasets were discarded. A total of 473 
candidate transcript pairs remained after this step.
Final selection step. Finally, a greedy forward search was performed on the reduced pool of highest-ranked 
RNA transcript pairs according to previously described methods41. The end product of this search was the 
final pan-viral signature containing two upregulated and two down regulated RNA transcripts as a linear sum 
(ISG15 + OASL) - (IL16 + ADGRE5).
Validation in independent GEO datasets. The pan-viral signature was then tested against 11 independ-
ent “validation” datasets (Table 3). These datasets were derived from six mammalian species (human, macaque, 
chimpanzee, pig, mouse and rat), all seven Baltimore groups, and various tissue types (blood, liver biopsies, in 
vitro primary hepatocytes), and included time course and vaccination studies in humans. It should be noted that 
differences in the y-axis scale (pan-viral signature value) between various studies, as indicated in figures in the 
text and Supplementary Material, result from differences in the various gene expression measurement platforms 
across studies.
Validation in independent clinical studies. The pan-viral signature received additional validation from 
two independent clinical studies, FEVER and GAPPSS, which were conducted on adult and pediatric patients 
respectively. Details of the FEVER study are provided in Supplementary Tables S1 and S2, Figure S6 and Text S1, 
and details of the GAPPSS study are provided in Supplementary Tables S3 and S4, Text S2, and the publication by 
Zimmerman et al.40 The GAPPSS study was an institutional review board-approved prospective, observational 
study (Seattle Children’s Hospital IRB #14761). Parental informed permission was obtained prior to sample and 
data collection. All sample and data collection was carried out in accordance with approved protocols and proce-
dures. The FEVER study was also an institutional review board-approved prospective, observational study (UK 
National Research Ethics services reference number: 09/H0701/103). All participants provided written informed 
consent, prior to sample and data collection. All sample and data collection was carried out in accordance with 
approved protocols and procedures.
The FEVER study cohort consisted of adult patients presenting with fever to the Emergency Department, and 
then admitted to hospital. A comparison was made between those retrospectively diagnosed with a viral infec-
tion (n = 15), with bacterial sepsis (n = 55) or with infection-negative SI (n = 22). In the FEVER study, testing 
for viral infections was only performed on those patients suspected of a viral infection, and involved use of one 
or more single-virus diagnostic tests based on the clinician’s judgment and according to hospital procedures85 
(e.g. PCR for influenza, serology for dengue, etc.). The GAPPSS study cohort consisted of pediatric intensive 
care patients retrospectively diagnosed with a viral infection (n = 5), bacterial sepsis (n = 25), or bacterial sepsis 
with a viral co-infection (n = 10), as well as infection-negative SI controls undergoing cardio-pulmonary bypass 
surgery (n = 29). All patients in the GAPPSS study, except for one bacterial sepsis patient who was omitted from 
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the analysis, were tested for the presence of viral nucleic acid sequences in nasal swabs using the Biofire FilmArray 
Respiratory Panel (Biofire Diagnostics, Utah, USA). Supplementary Tables S3 and S4 present the relative gene 
expression values for ISG15, IL16, OASL, ADGRE5 derived from RNA-seq data for the FEVER and GAPPSS 
patients, respectively. For each of the two datasets (FEVER or GAPPSS), we represented the expression level of 
a gene of interest by Fragments Per Kilobase of transcript per Million mapped reads (FPKM)86. This measure 
of gene expression should be independent of whether the data are in the form of single-end reads (FEVER) or 
paired-end reads (GAPPSS).
Combination of SeptiCyte™ LAB and pan-viral signature. To demonstrate utility of a combined 
bacterial and viral host response assay, we analysed GEO dataset GSE63990 using an 8-gene classifier consisting 
of the four pan-viral signature genes (IL16, ISG15, OASL, ADGRE5) combined with the four genes (CEACAM4, 
LAMP1, PLA2G7, PLAC8) from SeptiCyteTM LAB. The class labels used in GSE63990 were: bacterial infection, 
viral infection, and non-infectious illness. Line data from GSE63990 are presented in Supplementary Table S5. 
To assess whether a significant biological response exists from the eight genes, we performed a permutation test. 
Under this statistical framework the dependency between the feature space and the response (class labels) is 
broken thus allowing us to understand the behavior of the model under the null hypothesis that the explanatory 
variables and response labels are independent. The model, in this case, consisted of a supervised Random Forest 
analysis43 constructed from 1000 trees and allowing √f features to be selected randomly at each split, where f = 8 
and represents the number of gene targets. The class labels were then randomly permuted 2,000 times which 
allowed for a 0.05 alpha level with a 0.01 precision87. The data were then modeled using Random Forests. For 
each null model the multiclass log-loss was calculated to construct the null distribution before assessing the true 
response labels against the final null model.
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